Was gibt es Neues bei der Multiplen Sklerose?

 

 Buy Article Permissions and Reprints

Zusammenfassung

Im Jahr 2011 wurden die Ergebnisse einer Reihe interessanter klinischer Phase II und III Studien bei Patienten mit schubförmiger Multipler Sklerose (MS) vorgestellt oder publiziert. Hierbei handelt es sich zum einen um Studien mit neuen oralen Substanzen wie z. B. Laquinimod, Teriflunomid oder BG-12, zum anderen um Studien, welche die Effekte sogenannter „Biologicals“ untersuchten, also Substanzen mit hoher biologischer Wirksamkeit und gezielter hochselektiver Wirkweise. Auf Basis positiver Phase III Studienergebnisse wurden die Zulassungsverfahren bei einigen Substanzen initiiert (BG-12, Teriflunomid, Alemtuzumab, Laquinimod). Es gab jedoch auch unerwartete Ergebnisse, welche zumindest teilweise auf Besonderheiten der jeweiligen Studienpopulationen mit überraschend niedriger Schubaktivität und geringer Behinderungsprogression zurückzuführen sind, teils durch Imbalancen der jeweiligen Subgruppen in Folge der Randomisierung erklärt werden können. Darüber hinaus wurden im Jahr 2011 interessante neue Ergebnisse zu Genetik und Umweltfaktoren, Immunologie und Diagnostik vorgestellt und publiziert. In diesem Artikel möchten wir einen Überblick über die jüngsten Entwicklungen auf dem Gebiet der MS geben und die wichtigsten und interessantesten Ergebnisse aus dem Bereich der MS-Therapie zusammenfassen und vorstellen.

Abstract

In 2011, the results of a number of interesting clinical phase II and III studies on patients suffering from relapsing-remitting multiple sclerosis have been presented or published. These included studies investigating not only the anti-inflammatory potential of newly developed oral drugs such as laquinimod, teriflunomide or BG-12, but also the so-called biologicals, i. e., drugs with high biological activity and highly selective mode of action. Some of the positive clinical phase III studies resulted in initiation of the respective approval procedures for some of these substances such as, for example, BG-12, teriflunomide, and alemtuzumab. However, there were also some disappointments and unexpected results, which can at least partially be explained by imbalances in the study populations and by unexpectedly low rates of clinical signs of disease activity in the control groups. Moreover, very interesting new results in the fields of genetics and environmental factors, immunology and diagnostics were presented in 2011. This review reports on the latest findings and developments in the area of MS research and therapy from 2011.

• Literatur

• 1 Weber F, Fontaine B, Cournu-Rebeix I et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008; 9: 259-263
  CrossrefPubMedGoogle Scholar
• 2 Hoffjan S, Akkad DA. The genetics of multiple sclerosis: an update 2010. Mol Cell Probes 2010; 24: 237-243
  CrossrefPubMedGoogle Scholar
• 3 Sawcer S, Hellenthal G, Pirinen M et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214-219
  CrossrefPubMedGoogle Scholar
• 4 Munger KL, Levin LI, Hollis BW et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838
  CrossrefPubMedGoogle Scholar
• 5 Pierrot-Deseilligny C, Souberbielle JC. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?. Brain 2010; 133: 1869-1888
  CrossrefPubMedGoogle Scholar
• 6 Simpson Jr S, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193-203
  PubMedGoogle Scholar
• 7 Mowry EM, Krupp LB, Milazzo M et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010; 67: 618-624
  PubMedGoogle Scholar
• 8 von Essen MR, Kongsbak M, Schjerling P et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11: 344-349
  CrossrefPubMedGoogle Scholar
• 9 Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009; 132: 1146-1160
  CrossrefPubMedGoogle Scholar
• 10 Kimball SM, Ursell MR, O’Connor P et al. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 2007; 86: 645-651
  PubMedGoogle Scholar
• 11 Stein MS, Liu Y, Gray OM et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011; 77: 1611-1618
  CrossrefPubMedGoogle Scholar
• 12 Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol 1980; 37: 94-96
  CrossrefPubMedGoogle Scholar
• 13 Serafini B, Rosicarelli B, Franciotta D et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899-2912
  CrossrefPubMedGoogle Scholar
• 14 Lassmann H, Niedobitek G, Aloisi F et al. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue – report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain 2011; 134: 2772-2786
  CrossrefPubMedGoogle Scholar
• 15 Lucas RM, Ponsonby AL, Dear K et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 2011; 77: 371-379
  CrossrefPubMedGoogle Scholar
• 16 Tzartos JS, Khan G, Vossenkamper A et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012; 78: 15-23
  CrossrefPubMedGoogle Scholar
• 17 Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688
  CrossrefPubMedGoogle Scholar
• 18 Leandro MJ, Cambridge G, Ehrenstein MR et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-620
  CrossrefPubMedGoogle Scholar
• 19 Martin Mdel P, Cravens PD, Winger R et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009; 66: 1016-1020
  CrossrefPubMedGoogle Scholar
• 20 Bar-Or A, Fawaz L, Fan B et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann Neurol 2010; 67: 452-461
  CrossrefPubMedGoogle Scholar
• 21 Weber MS, Prodhomme T, Patarroyo JC et al. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell deple­tion in central nervous system autoimmunity. Ann Neurol 2010; 68: 369-383
  CrossrefPubMedGoogle Scholar
• 22 Lyons JA, San M, Happ MP et al. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 1999; 29: 3432-3439
  CrossrefPubMedGoogle Scholar
• 23 Harp CT, Ireland S, Davis LS et al. Memory B cells from a subset of treatment-naive relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-gamma production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 2010; 40: 2942-2956
  CrossrefPubMedGoogle Scholar
• 24 Fillatreau S, Sweenie CH, McGeachy MJ et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950
  CrossrefPubMedGoogle Scholar
• 25 Hirotani M, Niino M, Fukazawa T et al. Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol 2010; 221: 95-100
  CrossrefPubMedGoogle Scholar
• 26 Knippenberg S, Peelen E, Smolders J et al. Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive/memory Breg ratio during a relapse but not in remission. J Neuroimmunol 2011; 239: 80-86
  CrossrefPubMedGoogle Scholar
• 27 Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008; 255 (Suppl. 01) 3-11
  PubMedGoogle Scholar
• 28 Diestel A, Aktas O, Hackel D et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J Exp Med 2003; 198: 1729-1740
  CrossrefPubMedGoogle Scholar
• 29 Mildner A, Mack M, Schmidt H et al. CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009; 132: 2487-2500
  CrossrefPubMedGoogle Scholar
• 30 Ajami B, Bennett JL, Krieger C et al. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011; 14: 1142-1149
  CrossrefPubMedGoogle Scholar
• 31 Berer K, Mues M, Koutrolos M et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011; 479: 538-541
  CrossrefPubMedGoogle Scholar
• 32 Lee YK, Menezes JS, Umesaki Y et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011; 108 (Suppl. 01) 4615-4622
  CrossrefPubMedGoogle Scholar
• 33 Esplugues E, Huber S, Gagliani N et al. Control of TH17 cells occurs in the small intestine. Nature 2011; 475: 514-518
  CrossrefPubMedGoogle Scholar
• 34 Morris Z, Whiteley WN, Longstreth Jr WT et al. Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2009; 339: b3016
  CrossrefPubMedGoogle Scholar
• 35 Lebrun C, Bensa C, Debouverie M et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 2009; 66: 841-846
  CrossrefPubMedGoogle Scholar
• 36 Okuda DT, Mowry EM, Beheshtian A et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009; 72: 800-805
  CrossrefPubMedGoogle Scholar
• 37 Okuda DT, Mowry EM, Cree BA et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011; 76: 686-692
  CrossrefPubMedGoogle Scholar
• 38 De Stefano N, Stromillo ML, Rossi F et al. Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. PLoS One 2011; 6: e19452
  CrossrefPubMedGoogle Scholar
• 39 Costello F, Coupland S, Hodge W et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59: 963-969
  CrossrefPubMedGoogle Scholar
• 40 Costello F, Hodge W, Pan YI et al. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler 2008; 14: 893-905
  CrossrefPubMedGoogle Scholar
• 41 Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006; 113: 324-332
  CrossrefPubMedGoogle Scholar
• 42 Syc SB, Saidha S, Newsome SD et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain 2011;
  PubMedGoogle Scholar
• 43 Dorr J, Wernecke KD, Bock M et al. Association of retinal and macular damage with brain atrophy in multiple sclerosis. PLoS One 2011; 6: e18132
  CrossrefPubMedGoogle Scholar
• 44 Talman LS, Bisker ER, Sackel DJ et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 2010; 67: 749-760
  PubMedGoogle Scholar
• 45 Galetta KM, Calabresi PA, Frohman EM et al. Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics 2011; 8: 117-132
  CrossrefPubMedGoogle Scholar
• 46 Warnke C, Adams O, Gold R et al. Progressive multifocal leukoencephalopathy under natalizumab: Initial possibilities for risk stratification?. Nervenarzt 2011; 82: 475-480
  CrossrefPubMedGoogle Scholar
• 47 Killestein J, Vennegoor A, Strijbis EM et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68: 392-395
  CrossrefPubMedGoogle Scholar
• 48 Borriello G, Prosperini L, Marinelli F et al. Observations during an elective interruption of natalizumab treatment: a post-marketing study. Mult Scler 2011; 17: 372-375
  CrossrefPubMedGoogle Scholar
• 49 West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol 2010; 68: 395-399
  CrossrefPubMedGoogle Scholar
• 50 Sangalli F, Moiola L, Radaelli M et al. What to expect after natalizumab in every-day clinical practice. Multiple Sclerosis 2011; 17: S405
  PubMedGoogle Scholar
• 51 Fox R, Kappos L, Cree B et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. Multiple Sclerosis 2011; 17: S509
  PubMedGoogle Scholar
• 52 Preiningerova J. Oral laquinimod therapy in relapsing multiple sclerosis. Expert Opin Investig Drugs 2009; 18: 985-989
  CrossrefPubMedGoogle Scholar
• 53 Polman C, Barkhof F, Sandberg-Wollheim M et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987-991
  CrossrefPubMedGoogle Scholar
• 54 Vollmer TL, Soelberg Sorensen P, Arnold DL et al. A Placebo-controlled and active comparator phase III trial (BRAVO) for relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011; 17: S507
  CrossrefPubMedGoogle Scholar
• 55 Thone J, Ellrichmann G, Seubert S et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 2012; 180: 267-274
  CrossrefPubMedGoogle Scholar
• 56 Korn T, Magnus T, Toyka K et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76: 950-960
  CrossrefPubMedGoogle Scholar
• 57 O’Connor P, Wolinsky JS, Confavreux C et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293-1303
  CrossrefPubMedGoogle Scholar
• 58 O’Connor P, Wolinsky JS, Confavreux C et al. Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical and MRI data 5 years after initial randomisation. Multiple Sclerosis 2011; 17: S414
  PubMedGoogle Scholar
• 59 Comi G, O’Connor P, Wolinsky JS et al. Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow-up. Multiple Sclerosis 2011; 17: S182
  PubMedGoogle Scholar
• 60 Gold R, Kappos L, Bar-Or A et al. Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: results from the phase III DEFINE trial. Multiple Sclerosis 2011; 17: S34
  PubMedGoogle Scholar
• 61 Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-174
  CrossrefPubMedGoogle Scholar
• 62 Linker RA, Lee DH, Ryan S et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134: 678-692
  CrossrefPubMedGoogle Scholar
• 63 Linker RA, Lee DH, Stangel M et al. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother 2008; 8: 1683-1690
  CrossrefPubMedGoogle Scholar
• 64 Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463-1472
  CrossrefPubMedGoogle Scholar
• 65 Selmaj K, Gold R, Kappos L et al. Safety and tolerability of BG-12 in the phase III DEFINE trial in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis 2011; 17: S451
  PubMedGoogle Scholar
• 66 Bielekova B, Richert N, Herman ML et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011; 77: 1877-1886
  CrossrefPubMedGoogle Scholar
• 67 Martin JF, Perry JS, Jakhete NR et al. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 2010; 185: 1311-1320
  CrossrefPubMedGoogle Scholar
• 68 Sheridan JP, Zhang Y, Riester K et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler 2011; 17: 1441-1448
  CrossrefPubMedGoogle Scholar
• 69 Giovannoni G, Gold R, Selmaj K et al. A randomized, double-blind, Plazebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial. Multiple Sclerosis 2011; 17: S508
  PubMedGoogle Scholar
• 70 Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis – A focus on alemtuzumab. Clin Immunol 2011;
  PubMedGoogle Scholar
• 71 Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801
  Google Scholar
• 72 Jones JL, Anderson JM, Phuah CL et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010; 133: 2232-2247
  CrossrefPubMedGoogle Scholar
• 73 Jones JL, Phuah CL, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-2061
  PubMedGoogle Scholar
• 74 Coles A, Brinar V, Arnold DL et al. Efficacy and safety results from CARE-MS I, a phase III study comparing alemtuzumab and interferonβ-1a. Multiple Sclerosis 2011; 17: S510
  PubMedGoogle Scholar
• 75 Hirotani M, Niino M, Sasaki H. The role of B cells in multiple sclerosis: implications for B-cell-targeted therapy. Curr Med Chem 2010; 17: 3215-3222
  CrossrefPubMedGoogle Scholar
• 76 Kappos L, Li D, Calabresi PA et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378: 1779-1787
  CrossrefPubMedGoogle Scholar
• 77 Kappos L, Li D, Calabresi P et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial. Multiple Sclerosis 2011; 17: S194
  PubMedGoogle Scholar
• 78 Kappos L, Hartung HP, Freedman MS et al. ATAMS: a randomised trial of the B-cell-targeting agent atacicept in patients with relapsing multiple sclerosis. Multiple Sclerosis 2011; 17: S40
  PubMedGoogle Scholar
• 79 Hartung HP, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010; 3: 205-216
  CrossrefPubMedGoogle Scholar